Our mission is to develop therapies that empower the immune system to combat neurodegeneration and our team is focused on developing treatments for some of the most challenging diseases facing our society. By harnessing advancements in genetics, immunology and neuroscience, we are pioneering the development of potential therapies to counteract the devastating progression of neurodegeneration. We are supported in this mission by experienced and accomplished scientists and clinicians, a novel portfolio of programs, leading healthcare investors, and pharma company partners, who share in our commitment to bettering the lives of patients and realizing a world where we make brain disorders history. As Vice President, Clinical Development, you will serve as Alector’s senior clinical development physician and a key clinical leader for AL137 as the program enters Phase 1 clinical trials. You will bring your medical judgment, scientific curiosity, and drug development experience to help translate an innovative program into meaningful clinical evidence. You will provide medical and clinical development leadership across the program, working closely with colleagues in Clinical Operations, Translational Medicine, Regulatory, Safety, Biometrics, and other functions. As the program clinical lead, you will have significant ownership and visibility, helping us make rigorous, patient-centered decisions as AL137 progresses through early clinical development. This role is designed for a leader and “go-getter” who thrives through influence and hands-on contribution.